Delivering on the Promise of
BISPECIFICS
State-of-the-art Bispecific Antibody Development
Delivering on the Promise of Bispecifics: State-of-the-Art Bispecific Antibody Development
That's the power you have with KBI and Selexis.
That's the power of together.
![selexis-kbi](https://www.kbibiopharma.com/hs-fs/hubfs/selexis-kbi.png?width=400&name=selexis-kbi.png)
BISPECIFICS WHITEPAPER
DOWNLOAD THE PDF TODAY
An off-the-shelf therapy that can be used immediately, rather than one that must be manufactured individually for each patient (such as chimeric antigen receptor T-cell therapies, or CAR-Ts), can be a lifesaving treatment for patients who encounter difficult-to-treat or rapidly progressing diseases, including many cancers.
The promise of bispecific antibodies (bsAbs) stems from their off-the-shelf nature and ability to bind to two or more epitopes, thereby performing multiple functions.
Given the complexity of bsAbs, a cell-line development platform for these proteins must contain three key features to be sufficiently robust for generating bsAbs:
- Stable and high expression of bsAbs
- Straightforward early screening
- A robust cell line that can handle stressors
Furthermore, advancing bsAbs from the bench into the clinic requires process development, analytical methods, and scale-up for cGMP manufacturing.
The Selexis/KBI partnership combines best-in-class cell line development with science-driven, experienced contract development and manufacturing in a leverageable, integrated workflow that generates high-quality clinical bulk drug substances under accelerated timelines.
![BispecificsWhitepaper_Cover_Shadow](https://www.kbibiopharma.com/hs-fs/hubfs/BispecificsWhitepaper_Cover_Shadow.png?width=541&height=729&name=BispecificsWhitepaper_Cover_Shadow.png)
© 2024 KBI Biopharma